Related Experiment Video

Updated: Jun 17, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

Ana M Mendes-Pereira1, Sarah A Martin, Rachel Brough

  • 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

EMBO Molecular Medicine
|January 6, 2010
PubMed

Insights

PTEN deficiency impairs DNA repair via homologous recombination (HR) in cancer cells. This HR defect sensitizes tumors to PARP inhibitors, suggesting broader clinical use beyond BRCA mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The phosphatase and tensin homolog (PTEN) gene is frequently mutated in human cancers.
  • PTEN plays a role in maintaining genome stability.
  • Homologous recombination (HR) is a critical DNA repair pathway.

Purpose of the Study:

  • To investigate the role of PTEN in DNA repair.
  • To determine if PTEN deficiency affects homologous recombination (HR).
  • To assess the therapeutic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in PTEN-deficient tumors.

Main Methods:

  • Utilized human tumor cell lines with varying PTEN status.
  • Assessed DNA repair capacity, specifically homologous recombination (HR) efficiency.
  • Evaluated the sensitivity of PTEN-deficient cells to PARP inhibitors in vitro and in vivo.

Main Results:

  • PTEN deficiency was found to cause a significant defect in homologous recombination (HR) in human tumor cells.
  • This HR deficiency rendered tumor cells more sensitive to PARP inhibitors.
  • Sensitivity to PARP inhibitors was observed both in laboratory experiments and in animal models.

Conclusions:

  • PTEN deficiency leads to homologous recombination (HR) defects, impacting cancer cell genome stability.
  • Tumor cells with PTEN mutations are sensitive to PARP inhibitors.
  • Clinical application of PARP inhibitors may benefit a wider patient population, including those with PTEN-mutant tumors, not just BRCA-mutated cancers.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter07:53

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter

Published on: April 17, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...